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Sirtuin is a nicotinamide adenine dinucleotide–dependent
deacetylase. One of its isoforms, Sirt1, is a key molecule in
glucose, lipid, and energy metabolism. The renal protective
effects of Sirt1 are found in various models of renal disorders
with metabolic impairment, such as diabetic nephropathy.
Protective effects include the maintenance of glomerular
barrier function, anti–fibrosis effects, anti–oxidative stress
effects, and regulation of mitochondria function and energy
metabolism. Various target molecules subject to direct
deacetylation or epigenetic gene regulation have been
identified as effectors of the renal protective function of
sirtuin. Recently, it was demonstrated that Sirt1 expression
decreases in proximal tubules before albuminuria in a mouse
model of diabetic nephropathy, and that albuminuria is
suppressed in proximal tubule–specific mice overexpressing
Sirt1. These findings suggest that decreased Sirt1 expression
in proximal tubular cells causes abnormal nicotine
metabolism and reduces the supply of nicotinamide
mononucleotide from renal tubules to glomeruli. This further
decreases expression of Sirt1 in glomerular podocytes and
increases expression of a tight junction protein, claudin-1,
which results in albuminuria. Activators of the sirtuin family
of proteins, including resveratrol, may be important in the
development of new therapeutic strategies for treating
metabolic kidney diseases, including diabetic nephropathy.
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THE FUNCTIONS OF SIRTUIN AND NICOTINE AMIDE
DINUCLEOTIDE METABOLISM
Recently, there has been an explosion of studies on sirtuin in
health and diseases. The founding member of the sirtuin gene
family was originally found in yeast as silent information
regulator 2, Sir2.1 In 1986, the Sir2 gene was isolated and
identified as a gene associated with lifespan of cells from
yeast.2 In late 1990s, a study demonstrated that deletion of
Sir2 shortens yeast life span and that Sir2 overexpression
extends yeast life span.3 Sir2 came to be known as a longevity-
related factor.4 However, a possible mechanism was not
elucidated until a study showing the true enzyme activity of
Sir2 as a nicotine amide dinucleotide (NAD+)–dependent
histone deacetylase.5 Sir2 comprises the class II family of
histone deacetylase enzymes. Unlike class I and class II, which
requires only zinc as a cofactor, Sir2 depends on NAD+ for
activation. In the presence of NAD+, Sir2 catalyzes the
conversion of an acetylated substrate to a deacetylated
substrate with O-acetyl-ADP-ribose and nicotinamide as side
products.6 Sirtuins are mammalian homologs of Sir2, which
are composed of seven isoforms Sirt1 to Sirt7. These seven
isoforms share the same universal catalytic core region
composed of 275 amino acids and show a diverse subcellular
localization. Sirt1, Sirt6, and Sirt7 are mainly found in the
nucleus, Sirt2 is in the cytoplasm, while Sirt3, Sirt4, and Sirt5
are localized in mitochondria.7 Among the seven isoforms,
Sirt1 is the most studied, is homologous to Sir2, and is
induced by calorie restriction, which has been verified as
a life-extending process in mammals (Figure 1). Since
substrates of Sirt1 vary from transcription factors that are
involved in energy metabolism, including glucose and lipid
metabolism, Sirt1 may have an important role in a number of
biological processes like cell apoptosis, cell survival, longevity,
and stress resistance. Human Sirt1 has been implicated to
have a role in a number of age-related diseases like diabetes,
neurodegenerative diseases, and kidney diseases. In particular,
Sirt1 deacetylates uncoupling protein-1, peroxisome
proliferator-activated receptor α, peroxisome proliferator-
activated receptor gamma coactivator α, and peroxisome
proliferator-activated receptor γ and increases their activities.8
Hence, the functions of Sirt1 are intimately related to
pathological conditions in diabetes and insulin resistance.
Systemic and liver-specific Sirt1 knockout leads to insulin
resistance in mice,9,10 and adipose tissue–specific Sirt1 knock-
out increases obesity in high-fat diet-fed mice.11 In parallel
with those observations, systemic Sirt1 transgenic mice show
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reduced insulin resistance,12 and adipose tissue–specific Sirt1
overexpression leads to reduced obesity in high-fat diet-fed
mice.11 Thus, Sirt1 enables effective use of biogenic energy
and increases insulin sensitivity.
As mentioned, Sirt1 catalyzes deacetylation with the aid of
the coenzyme NAD+, the cellular level of which is important
for its enzymatic activity. NAD+ is also important for
oxidizing and reducing reactions as a coenzyme. NAD+ is
synthesized through two biological pathways, these being
de novo synthesis using an essential amino-acid tryptophan
supplied by dietary intake, and a salvage pathway in which
NAD+ is resynthesized from nicotinamide (NAM). The rate-
limiting factor in the salvage pathway is nicotinamide
phosphoribosyltransferase (NAMPT), which catalyzes the
synthesis of nicotinamide mononucleotide (NMN) from
NAM and 5’-phosphoribosyl-1-pyrophosphate (Figure 2).13
Two NAMPT have been identified in mammals: intracellular
NAMPT (iNAMPT) and extracellular NAMPT (eNAMPT),
found in the circulation. iNAMPT is known to be involved
in energy metabolism.14 For instance, overexpression of
iNAMPT in the liver suppresses induction of hepatic
steatosis.15 It is also reported that systemic administration
of iNAMPT-expression vector alleviates abnormal glucose
tolerance.16 Calorie restriction increases the expression level
of iNAMPT in muscles and mitochondria.17 These effects
are possibly due to the activation of Sirt1, which is caused
by activation of iNAMPT, followed by an increase in NAD+
supply. Activation of Sirt1 leads to activation of the salvage
pathway through an increase in NAM and following activa-
tion of iNAMPT. At the same time, activation of Sirt1 leads to
suppression of the clock genes, thereby reducing iNAMPT
expression. This prevents excess activation of Sirt1 and
iNAMPT and an excess in the positive feedback loop.18,19
NAD, iNAMPT, and Sirt1 are currently recognized as
important new factors in energy metabolism.
THE RENAL PROTECTIVE EFFECTS OF SIRTUIN
Sirtuin increases resistance against acute stress and also
regulates energy metabolism. Increasing evidence suggests
that sirtuin provides protective effects against the onset and
development of various renal disorders.
Acute kidney injury
The renal protective effects of sirtuin have been demonstrated
using various models of acute kidney injury. For example,
using the cisplatin-induced kidney injury model, researchers
found that Sirt1 exhibited renal protective effects by
deacetylation of p53 and by inducing catalase activity, which
lead to anti–apoptotic and anti–oxidant effects, respectively.20
Deacetylation and activation of peroxisome proliferator-
activated receptor gamma coactivator 1-alpha by a specific
Sirt1 activator, SRT1720, increases biogenesis of mitochon-
dria, mitochondrial proteins as well as mitochondrial
respiration. As a result, a differentiated, polarized tubule
epithelium is restored, leading to a decrease in ischemia-
reperfusion injury by SRT1720.21 These functions are related
to the protection against acute tissue or cell insults by effective
energy utilization. It was recently reported that Sirt2 also
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Figure 1 | Sirtuins and their functions. Sirtuin, a mammalian
homolog of the Sir2 gene in yeasts, comprises seven isoforms. Sirt1, 6,
and 7 are located predominantly in the nucleus, Sirt2 in cytoplasm,
and Sirt3, 4, and 5 in mitochondria. These genes are activated or
induced by calorie restriction or by acute cellular stresses mainly
through increased levels of NAD+, thereby having a function in
cellular survival. Changes contribute to longevity and organ
protection. NAD, nicotine amide dinucleotide; Sirt, Sirtuin.
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Figure 2 |Nicotinic acid metabolism. NAD+, an essential factor in
cellular respiration and metabolism, is produced through metabolism
of nicotinic acid. NAD+ is synthesized via a de novo pathway from
essential amino acid. NAD+ is also recycled through a salvage
pathway where iNAMPT acts as a rate-limiting enzyme. In case
NAD+ salvage was insufficient, Sirt1 activity decreased, further
downregulating iNAMPT activity and salvage pathway. NAD, nicotine
amide dinucleotide; Npt, nicotinic acid phosphoribosyltransferase;
NaMN, nicotinic acid mononucleotide; Nmnat, nicotinamide
mononucleotide adenylyltransferase; NMN, nicotinamide
mononucleotide; iNAMPT, intracellular nicotinamide phosphoribosyl-
transferase; NMNAM, n-methylnicotinamide; Nnmt, nicotinamide
n-methyltransferase.
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exhibits a renal protective effect through deacetylation of
mitogen-activated protein kinase phosphatase-1 and the
p65 subunit of nuclear factor-κB (NF-κB) in the
lipopolysaccharide-induced acute kidney injury model. SIRT2
regulated p65 binding to the promoters of chemokines,
CXCL2 and CCL2 and expressions of these chemokines
leading to anti–inflammatory effects.22 Stanniocalcin (STC)-1
and -2 are secreted glycoproteins, which are known to
regulate serum calcium and phosphate homeostasis. STC1 is
important for activation of AMP kinase in the kidney, which
mediates STC1-induced expression of uncoupling protein-2
and Sirt3 leading to protection from ischemia-reperfusion
injury. The suppression of ischemia-reperfusion injury by
STC-1 is via anti–oxidant effect.23 All of these effects are
related to the anti–inflammatory and anti–oxidative effects of
sirtuin.
Renal fibrogenesis
Sirtuin prevents renal fibrogenesis in a model of unilateral
ureteral obstruction. Using an activator and inhibitor of
sirtuin, it was demonstrated that Sirt1 and Sirt2 suppressed
renal fibrogenesis by suppressing phosphorylation of STAT3
(signal transducer and activator of transcription 3), epidermal
growth factor receptor, and platelet-derived growth factor
receptor.24 Using Sirt1 heterozygous knockout mice, it was
also shown that Sirt1 suppressed oxidative stress and
inflammation in the interstitium through suppression of the
expression of cyclooxygenase-2 and inhibited renal oxidative
stress and fibrogenesis.25 Additionally, endothelial cell-
specific Sirt1 knockout mice showed significant increases of
folic acid–induced fibrogenesis. In the kidneys of endothelial
cell–specific Sirt1 knockout mice, impaired angiogenesis,
reduced matrilytic activity, and retention of the profibrotic
cleavage substrates tissue transglutaminase and endoglin
accompanied the suppressed expression of matrix metallo-
proteinase-14. The restoration of matrix metalloproteinase-14
expression in these mice improved angiogenic and matrilytic
functions of the endothelium, prevented renal fibrosis, and
ameliorated nephrosclerosis.26 Sirt1 was also shown to inhibit
the tissue fibrosis by deacteylating Smad4 and repressing the
effect of transforming-growth factor β signaling on a Smad4
target gene, matrix metalloproteinase-7. Consequently, less
E-cadherin is cleaved from the cell surface and β-catenin
remains bound to E-cadherin at the cell–cell junctions leading
to a reduced fibrosis.27
Cyst formation
The role of Sirt1 in renal cyst formation was recently
reported. Mice lacking both Pkd1, the causative gene for
polycystic kidney disease, and Sirt1 showed decreased
cyst formation. Administration of Sirt1 inhibitor to Pkd1
knockout mice decreased the cyst formation rate.28 Over-
expression of Sirt2 in renal epithelial cells disrupted the cilia
formation observed in the Pkd1 knockdown. The aberrant
centrosome amplification and polyploidy in Pkd1 mutant or
depleted cells in polycystic kidney disease was mediated
through overexpression of Sirt2.29 These functions of Sirt1
and Sirt2 suggest their involvement in cystic kidney disease
and ciliopathy-associated disease progression. In the former
study, Sirt1 induced renal epithelial cell proliferation by
inhibiting the function of both Rb and p53 through the
deacetylation of these molecules.28 This effect promotes
continuous epithelial cell growth and cyst formation, which
enhances the disease progression. On the other hand, this
effect is favorable for the recovery from the kidney damages
where epithelial cells are subjected to apoptosis in ischemia-
reperfusion injury or in acute tubular necrosis as already
described above. Therefore, the role of Sirtuin in the initiation
and progression of disease varies based on the disease
background.
Renal aging
Activation of sirtuin prevents age-related impairment in renal
functions. Mice lacking angiotensin II type 1a receptor show a
prolonged lifespan compared with wild-type mice. These
mice developed decreased cardiac and vascular injury, and
multiple organs from these mice show less oxidative damage
than wild-type mice. The increased number of mitochondria
and upregulation of Nampt and Sirt3 in the kidney were
associated with the longevity phenotype.30 Although calorie
restriction is known to extend the lifespan of mice, this
effect is canceled in Sirt1 heterozygous knockout mice.
Sirt1 mediates deacetylation of forkhead box (Fox) O3a
and induces expression of BCL2/adenovirus E1B 19-kDa
interacting protein 3 (Bnip3), which is a key molecule in
mitophagy, leading to longevity. This study highlights the role
of the Sirt1–Foxo3 axis in cellular adaptation to hypoxia.31
The aged kidney shows increased vulnerability to acute
stresses, such as ischemia-reperfusion. It has been reported
that the vulnerability of the aged kidney to acute injury
improves with administration of an activator of Sirt1,
SRT-1720, and is further impaired in Sirt1 heterozygous
knockout mice. The mechanisms underlying the protective
effect of Sirt1 include the suppression of cell apoptosis.32
Diabetic nephropathy
Many studies have examined the roles of sirtuin in the onset
and development of diabetic nephropathy. 3,5-diiodothyr-
onine activates Sirt1, which deacetylates and inactivates NF-
κB in mesangial cells. This results in suppression of
phosphorylation of c-JUN and suppression of mesangial
expansion and decreases urinary proteins.33 Sirtuin also has a
role in podocyte injury in diabetic nephropathy. Podocyte-
specific Sirt1 knockout mice show increased urinary proteins
in diabetic nephropathy, suggesting that Sirt1 deacetylates and
inactivates the p65 subunit of NF-κB and STAT3 and
suppresses impairment and dysfunction of podocytes.34 It is
also reported that Sirt1 deacetylates FoxO4 and decreases
expression of a pro-apoptotic factor, Bcl2L11. This results in
decreased apoptotic degeneration of podocytes and reduction
of urinary proteins.35
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The protective roles of sirtuin in kidney cells
The renal effects of sirtuin are conferred via activation of the
canonical molecular targets of sirtuin, such as PCG1α and
p53. Several reports have identified kidney cell–specific
pathways activated by sirtuin. For example, cortactin is an
F-actin binding protein involved in cell migration and
cytoskeleton organization in various cells including podo-
cytes. Sirt1 interacts with and induces deacetylation and
activation of cortactin. A recent study has revealed that Sirt1
is required for the maintenance of cytoskeletal integrity by
regulating cortactin function in podocytes. In podocyte-
specific Sirt1-deficient mice, increases in urinary albumin
excretion and severity of glomerular injury were significantly
greater compared with wild-type mice, and also exhibited
enhanced podocyte foot process effacement.36 By using Sirt3-
deficient embryonic fibroblasts, another study reported that
mitochondrial sirtuin, Sirt3 interacts with the 39-kDa protein
NDUFA9, a subunit of complex I in the mitochondrial
electron transfer system, thereby activating complex I and
increasing ATP production. In the kidney of Sirt3-deficient
mice, the basal ATP content decreased.37 In mouse mesangial
cells, Sirt1 interacts with and induces deacetylation of Smad7,
a mediator of transforming-growth factor β-induced cellular
apoptosis. Through this process, Sirt1 inhibits transforming-
growth factor β-induced mesangial cell apoptosis.38
Sirtuin activator
Sirtuin activator has gained increased attention as a potential
renoprotective agent based on the recently reported renal
protective effects of sirtuin. The most recognized activator of
Sirt1 is resveratrol, a type of polyphenol. The renal protective
effect of resveratrol was demonstrated in models of diabetic
nephropathy: the streptozotocin (STZ)-administered type 1
diabetes model39 and the type 2 diabetes db/db mice model.40
It is reported that resveratrol suppresses renal lesions in obesity-
related nephropathy, which is caused by a high-fat intake.41
Resveratrol also shows a renal protective effect in models of acute
kidney injury such as the cisplatin-induced model, the ischemia-
reperfusion injury model, and the sepsis-associated model.42–44
The current mechanisms proposed for how resveratrol
exhibits its renal protective effects include various path-
ways besides activation of Sirt1; for example, activation of
AMPK or superoxide dismutase 2, and anti–oxidant and
anti–inflammatory effects. A synthetic activator of Sirt1,
SRT1720, has also been reported to have a renal protective
effect in a model of ischemia-reperfusion injury.45 However,
these studies were conducted using rodent models, and it is
necessary to examine the effects of sirtuin activators in
humans, with particular attention being paid to the dosage.
Human studies
Despite its apparent pivotal role in the pathogenesis of kidney
disease, clinical evidence showing the relationship between
Sirt1 expression and human disease progression is scarce.
One study examined the relationship between the biological
properties of kidney tumors and Sirt1 expression and found
that mutated alleles of Sirt1 in tumor samples of hereditary
type 2 papillary renal cell carcinoma caused activation of the
tumor-related gene, nuclear factor-like 2.46 Another study
examined the expression of Sirt1 in peripheral mononuclear
cells of patients with stage 2 and 3 chronic kidney disease
and found that treatment with the phosphate-lowering
reagent, sevelamer carbonate, lowered serum inflammatory
markers and increased mRNA expression of Sirt1 in periph-
eral mononuclear cells. These findings suggest novel actions
of sevelamer carbonate on metabolic and inflammatory
abnormalities in early diabetic chronic kidney disease.47
Using human kidney biopsy samples, a novel pathogenic
mechanism was confirmed in diabetic nephropathy where
the lack of glomerular Sirt1 epigenetically increased the
expression of the tight junction protein claudin-1, thereby
aggravating proteinuria.48 This study is discussed below.
SIRT1 EXPRESSION IN PROXIMAL TUBULES AND ABNORMAL
NICOTINE METABOLISM IN DIABETES
Recently, the disease-initiating role of metabolic disruption in
proximal tubular cells is reported in diabetic nephropathy,
which is triggered by downregulation of Sirt1 (Figure 3).48
Proximal tubule–specific Sirt1 genetically modified mice
Proximal tubules, which actively mediate reabsorption and
require vast quantities of energy, suggesting the potential
importance of Sirt1 in this tissue. Sirt1 is also thought to
have a critical role in nephropathy and renal injury in
diabetes, an energy metabolism dysfunction disease. The
biological significance of Sirt1 was examined using proximal
tubule–specific Sirt1 genetically modified mice. In STZ-
NMN
iNAMPT
Sirt1
Sirt1
Histone H3K9
acetylation
CpG
methylation
Claudin-1
Podocin/
synaptopodin
Foot process
effacement
Albuminuria
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Figure 3 | Tubule–glomeruli communication hypothesis. Primary
downregulation of Sirtuin (Sirt1) or iNAMPT reflects metabolic
disruption of proximal tubular cells in the diabetic condition and
initiates albuminuria. This downregulation decreases NMN excretion
from proximal tubules, which is taken up by podocytes upstream and
close to proximal tubules. Reduced uptake levels of NMN decrease
Sirt1 expression in podocytes, which epigenetically upregulate
claudin-1 expression through increased acetylation of histone H3K9
and through the hypermethylation of the claudin-1 gene CpG island.
Ectopic overexpression of claudin-1 in podocytes disrupts the slit
membrane structure via reduced expression of synaptopodin and
podocin. This molecular change leads to changes in the podocyte
structure and foot process effacement. Finally, the molecular events
propagating proximal tubular cells to podocytes initiate albuminuria
in diabetic nephropathy. NMN, nicotinamide mononucleotide;
iNAMPT, intracellular nicotinamide phosphoribosyltransferase.
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induced diabetic mice models, expression of Sirt1 in proximal
tubules of wild-type mice was significantly reduced at
8 weeks after STZ administration, and further reduced at
24 weeks. Reduction in glomeruli was first observed at 24 weeks
after administration. At 8 weeks, serum glucose increased,
whereas albuminuria, signifying glomerular failure, was not
yet observed, indicating that proximal tubule integrity was
disrupted at the molecular level before glomerular failure.
Overexpression of Sirt1 in proximal tubules of transgenic
mice improved the downregulation of Sirt1 not only in
proximal tubules but also in podocytes at 24 weeks after
STZ administration. Although Sirt1 was overexpressed only
in proximal tubules and serum glucose levels did not fall
in transgenic mice, albuminuria at 24 weeks was scarcely
detected and foot process effacement of podocytes was
mitigated. The amelioration of albuminuria in transgenic mice
was not complete and it is deduced that Sirt1 over-
expression in proximal tubules followed by Sirt1 recovery in
podocytes overcame, to a certain extent, a harmful influence of
high glucose on podocytes.
Gene profiling showed a significant difference in expres-
sion levels of claudin-1, a tight junction component, between
STZ-treated wild-type and transgenic mice. In wild-type mice,
claudin-1 expression was only detected in parietal epithelial
cells (PEC) of the Bowman’ capsule, and was strongly
expressed in PEC and glomerular podocytes in the diabetic
model. The increased expression was suppressed in transgenic
mice. Using laser microdissection, it was observed that STZ
administration in wild-type mice resulted in decreased Sirt1
expression in both proximal tubules and PEC and increased
claudin-1 expression in PEC. In transgenic mice, although the
mice overexpressed Sirt1 only in proximal tubules, the Sirt1
expression level increased also in PEC, and claudin-1
expression decreased in PEC.
Introduction of claudin-1 expression vector into cultured
podocytes led to suppression of podocin and synaptopodin
expression, which regulate the albumin permeability of
podocytes. Furthermore, the injection of claudin-1 gene-
integrated Sendai virus vector successfully led to overexpres-
sion of claudin-1 protein in the kidneys of wild-type mice
and resulted in increased albuminuria and aggravation of
podocyte foot process effacement.48
Sirt1-mediated epigenetic gene regulation
The molecular mechanism of claudin-1 expression was
examined using human renal epithelial cells. High concentra-
tion of glucose upregulated and overexpression of Sirt1
downregulated claudin-1 expression, respectively. Focused
on the epigenetic regulatory mechanism by Sirt1 as a histone
deacetylase, it was found that both mouse and human
claudin-1 promoter contained CpG regions that are con-
sensus gene sequences for methylation modification.
Methylation-specific PCR analysis revealed that high glucose
increased, and Sirt1 overexpression decreased, methylation of
claudin-1 gene. Silencing DNA methyltransferase 1 (Dnmt1)
abrogated Sirt1-mediated claudin-1 gene methylation. In
addition, a chromatin immunoprecipitation assay showed
that Sirt1 induced histone H3K9 deacetylation. Thus, Sirt1
activation epigenetically suppressed claudin-1 expression via
histone H3K9 deacetylation and Dnmt1-mediated CpG
methylation in podocytes and PEC. The diabetic condition
resulted in a downregulation of Sirt1 in podocytes, which
reduced claudin-1 gene methylation and increased claudin-1
gene expression.
In renal biopsy samples from patients with diabetic
nephropathy, intrarenal expression of Sirt1 in both proximal
tubular and glomerular regions decreased, and claudin-1
expression in the glomerular region increased, in the kidneys
of patients with heavy proteinuria compared with those with
moderate proteinuria. Claudin-1 expression negatively corre-
lated with Sirt1 expression in both proximal tubules and
glomerular regions. Among several clinical parameters, only
proteinuria correlated with both proximal tubular and
glomerular Sirt1 immunostaining and also with glomerular
claudin-1 immunostaining. Methylation levels of claudin-1
gene negatively correlated with claudin-1 expression levels,
confirming epigenetic gene regulation of claudin-1 expression
in human samples.48
Renal tubule–glomeruli communication hypothesis and its
mediator
These data implied that decreased Sirt1 expression in proxi-
mal tubules leads to a decrease in glomerular Sirt1 and
subsequent upregulation of glomerular claudin-1. It was
thought that the release of an unknown mediator from
proximal tubules affected Sirt1 expression in podocytes
and glomeruli. The authors48 named such a potential retro-
grade functional association between proximal tubules
and glomeruli as ‘renal tubule–glomeruli communication’
(Figure 3). In in vitro experiment, conditioned medium
obtained from proximal tubule cells cultured with high
glucose medium led to significant suppression of Sirt1 and
upregulation of claudin-1 in cultured podocytes. This result
suggested that there was a humoral factor secreted from
proximal tubule cells that regulated Sirt1 and claudin-1
expressions in podocytes. NMN is an intermediary metabolite
of nicotinic acid metabolism (Figure 1), and its generation
decreases when Sirt1 activity decreases. In the previous report,
NMN is secreted from perivascular adipose tissue and
alters vascular smooth muscle cell morphology, suggesting
its function as a mediator for cell-to-cell interaction.49 In
proximal tubule cells, NMN decreased when cells were
cultured with high glucose. Addition of NMN to the
conditioned medium obtained from proximal tubule cells
cultured with high glucose medium restored Sirt1 expression
and reduced claudin-1 expression in podocytes. Fluorescence
staining for NMN showed that the intracellular NMN level
decreased in proximal tubule cells cultured with high glucose.
The NMN level also decreased in the kidney of STZ-
administered diabetic mice, and did not change in transgenic
mice. Intrarenal administration of fluorescent-labeled NMN
showed NMN first accumulated mainly in the renal tubule 1 h
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after administration, and was subsequently transferred to
glomeruli 2–4 h after administration.
These sets of experiments provide the evidence for NMN
as a mediator of renal tubule–glomeruli communication.
Similar events are not detected in the 5/6 renal ablation
model, suggesting that hyperglycemic stimulation is impor-
tant in the pathological process. Consistently, in this study,
essential parts of the results in STZ-induced diabetic mice
were reproduced not only in obese-type diabetic db/db mice
but also in the db/db mice crossed with proximal tubule–
specific Sirt1 transgenic mice. Moreover, the phenotypes
observed in diabetic mice were reproduced in tissue culture
systems using proximal tubular cell line, HK-2 cell, and
primary podocytes exposed to high glucose. The phenotypes
in STZ-treated mice in this study are primarily due to diabetic
condition, but not to STZ-induced nephrotoxicity.
NAMPT and sirtuin
Since NAMPT is a key NAD biosynthetic enzyme, it is
suggested that iNMPT in proximal tubules played a crucial
role in regulating Sirt1 activity in the kidney. The expression
of iNAMPT is predominantly in tubular cells.48 Consistently,
the concentration of NMN in the tubular area was greater
than that in the glomerular area in normal mice, although
these levels decreased in diabetic mice. The treatment with
an iNAMPT inhibitor, FK866, provoked proteinuria in
normal mice, suggesting that Sirt1 downregulation in podo-
cytes with the onset of diabetic nephropathy was caused by
the preceding downregulation of iNAMPT in proximal
tubules.48
PERSPECTIVE
Sirt1 is a key molecule in cellular energy metabolism and
exhibits renal protective effects through deacetylation and
regulation of various factors such as p53, NF-κB p65 subunit,
STAT, FoxO1, and FoxO3, which are transcriptional factors
related to apoptosis, cellular aging, and inflammation
(Figure 4). Sirtuin also exhibits histone deacetylation activity
and renal protective effects through epigenetic regulation of
gene expression. Recent study identified claudin-1 gene as a
new target of epigenetic regulation by Sirt1. There have been
few studies examining the epigenetic function–mediated renal
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Figure 4 | Scheme depicting the role of sirtuin in kidney disease. Sirt1 and Sirt3 have significant roles in the pathogenesis of various kidney
diseases and in renal damage. These effects were targeted at various sites or cells of the kidney and at various downstream molecules that were
subject to deacetylation or epigenetic gene regulation by sirtuin. AKI, acute kidney injury; MMP14, matrix metalloproteinase 14; NF-κB, nuclear
factor-κB; PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; Sirt, Sirtuin.
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protective effect of Sirt1, which remains to be elucidated. In
addition to Sirt1, Sirt2 and Sirt3 also function in the kidney.
It is therefore important to examine their roles in kidney
diseases. In addition, the development of a kidney-specific
sirtuin activator may be useful as a therapeutic agent for
treatment of renal disorders.
Also of interest is elucidating the significance of NAMPT
in kidney diseases, as NAMPT is a key molecule in nicotinic
acid metabolism through which NAD+, the most important
factor for regulation of sirtuin activity in vivo, is supplied. The
role of iNAMPT as an activator of Sirt1 was reported in a
recent study.19 Intriguingly, iNAMPT is expressed only in
renal tubules and not in glomeruli. It is suggested that organs
with low iNAMPT activity such as pancreatic β cells, neural
tissues, and adipose tissues could be metabolic frailty points,
and metabolic energy failure may be propagated from there
throughout the entire body.13 The activity of iNAMPT is low
in glomerulus-forming cells such as podocytes, mesangial
cells, and endothelial cells, and thus NAD+ is easily depleted
in glomeruli. Therefore, the NAD+ supply from renal tubules
is necessary and reduction of iNAMPT expression in proximal
tubules could be intimately related to the pathological
development of diseases. Future studies using proximal
tubule–specific iNAMPT gene–modified mice would solve
these issues. These studies also will reveal the significance of
iNAMPT in renal diseases.
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